This session from Heart World Conference (HWC) 2026 focuses on the clinical management of cardiomyopathies with an emphasis on the prevention of sudden cardiac death (SCD). It covers current approaches to genetic testing in hypertrophic, dilated, and arrhythmogenic cardiomyopathies, and their role in identifying at-risk individuals. Risk stratification tools—including advanced imaging, electrocardiographic markers, and family history—will be examined in the context of selecting patients for implantable cardioverter-defibrillator (ICD) therapy. The session also highlights the importance of individualized care pathways, early identification, and ongoing monitoring to reduce SCD risk in this population.